RhyGaze

Gene therapy. For sight.

Basel, Switzerland · $96.0M raised

Headquarters
Basel
Business Model
B2B
Total Funding
$96.0M
Last Round
$86.0M Series AJan 2025
Rounds
2

About

RhyGaze is a gene therapy company developing treatments to restore sight for people living with vision loss caused when cells in the eye lose the ability to convert light into an electrical signal. Its platform originated at the Institute of Molecular and Clinical Ophthalmology Basel, where researchers combined optogenetic proteins that engineer photosensitivity into mammalian cells with gene therapy tools that install that light-sensing machinery in target cells of the human eye. The team includes veterans of Luxturna, the first FDA-approved gene therapy for a genetic disease, and the company is based in Basel, Switzerland and Philadelphia, Pennsylvania.

Summary

RhyGaze is a Biotech company based in Basel, Switzerland. It has raised $96.0M in total across 2 rounds, most recently a $86.0M Series A round in Jan 2025. Investors include BioGeneration Ventures, GV and Novartis Venture Fund.

Tech & App Stack

1 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series ASeries AJan 2025
$86.0M

Sign up to see all 2 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

RhyGaze on Indexed.vc
<a href="https://indexed.vc/companies/rhygaze"><img src="https://indexed.vc/api/badge/company/rhygaze" alt="RhyGaze on Indexed.vc" width="260" height="76" /></a>